Journal
CHEMICAL COMMUNICATIONS
Volume 58, Issue 31, Pages 4825-4836Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d2cc00341d
Keywords
-
Categories
Funding
- DST, Government of India [DST/INSPIRE/04/2019/000492]
- Royal Society (Newton International Fellowships Alumni 2021) [AL\211023]
- Indian Institute of Technology (BHU)
- Ministry of Education, the Government of India
- CSIR, the Government of India
Ask authors/readers for more resources
In response to the increasing mortality rate associated with cancer and the limitations of Pt-based chemotherapeutics, the concept of catalytic anticancer agents has been introduced, showing promising results with Os(ii) complexes in disrupting essential intracellular processes in cancer cells, ultimately leading to cell death. These complexes have the potential to be novel catalytic cancer drugs with unique anticancer mechanisms.
The recent dramatic enhancement in cancer-related mortality and the drawbacks (side effects and resistance) of Pt-based first-generation chemotherapeutics have escalated the need for new cancer medicines with unique anticancer activities for better human life. To overcome the demerits of Pt-based cancer drugs, the concept of catalytic anticancer agents has recently been presented in the field of anticancer metallodrug development research. Many intracellular transformations in cancer cells are catalyzed by metal complexes, including pyruvate reduction to lactate, NAD(P)(+) reduction to NAD(P)H and vice versa, and the conversion of O-3(2) to reactive oxygen species (ROS). These artificial in-cell changes with non-toxic and catalytic dosages of metal complexes have been shown to disrupt several essential intracellular processes which ultimately cause cell death. This new approach could develop potent next-generation catalytic anticancer drugs. In this context, recently, several 16/18 electron Os(ii)-based complexes have shown promising catalytic anticancer activities with unique anticancer mechanisms. Herein, we have delineated the catalytic anticancer activity of Os(ii) complexes from a critical viewpoint. These catalysts are reported to induce the in-cell catalytic transfer hydrogenation of pyruvate and important quinones to create metabolic disorder and photocatalytic ROS generation for oxidative stress generation in cancer cells. Overall, these Os(ii) catalysts have the potential to be novel catalytic cancer drugs with new anticancer mechanisms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available